KRW 1446.0
(-0.69%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 17.95 Billion KRW | 118.02% |
2022 | 8.23 Billion KRW | 1239.02% |
2021 | 615.02 Million KRW | -66.62% |
2020 | 1.84 Billion KRW | 69.33% |
2019 | 1.08 Billion KRW | 97.83% |
2018 | 550 Million KRW | 0.0% |
2017 | 550 Million KRW | 0.0% |
2016 | 550 Million KRW | 0.0% |
2015 | 550 Million KRW | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 16.99 Billion KRW | -5.35% |
2024 Q2 | 10.74 Billion KRW | -36.76% |
2023 Q2 | 15.74 Billion KRW | -45.38% |
2023 Q1 | 28.82 Billion KRW | 250.0% |
2023 FY | 17.95 Billion KRW | 118.02% |
2023 Q4 | 17.95 Billion KRW | 6.36% |
2023 Q3 | 16.88 Billion KRW | 7.23% |
2022 FY | 8.23 Billion KRW | 1239.02% |
2022 Q4 | 8.23 Billion KRW | -69.54% |
2022 Q3 | 27.03 Billion KRW | 2.73% |
2022 Q2 | 26.31 Billion KRW | 31.64% |
2022 Q1 | 19.99 Billion KRW | 3150.33% |
2021 Q2 | 1.35 Billion KRW | -22.38% |
2021 Q3 | 732.38 Million KRW | -45.86% |
2021 FY | 615.02 Million KRW | -66.62% |
2021 Q4 | 615.02 Million KRW | -16.02% |
2021 Q1 | 1.74 Billion KRW | -76.34% |
2020 Q3 | 7.16 Billion KRW | 0.0% |
2020 FY | 1.84 Billion KRW | 69.33% |
2020 Q1 | - KRW | -100.0% |
2020 Q4 | 7.36 Billion KRW | 2.84% |
2019 Q4 | 859.41 Million KRW | 0.0% |
2019 FY | 1.08 Billion KRW | 97.83% |
2018 FY | 550 Million KRW | 0.0% |
2017 FY | 550 Million KRW | 0.0% |
2016 FY | 550 Million KRW | 0.0% |
2015 FY | 550 Million KRW | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 697.79 Million KRW | -2473.09% |
InBody Co.,Ltd | 6.08 Billion KRW | -195.297% |
Curexo Inc. | 2.05 Billion KRW | -771.866% |
Seegene, Inc. | 141.76 Billion KRW | 87.335% |
i-SENS, Inc. | 143.79 Billion KRW | 87.513% |
Ray Co., Ltd. | 86.67 Billion KRW | 79.286% |
Sugentech Inc. | 15.3 Billion KRW | -17.325% |
L&C Bio Co., Ltd | 82.13 Billion KRW | 78.14% |